Trident Texofab Releases Q2 FY25 Financial Results: PAT and EPS Show Positive Trend, PBT and PBDIT Decline

Trident Texofab, a microcap trading company, has recently announced its financial results for the quarter ending September 2024. The company’s stock has been given a ‘Strong Sell’ rating by MarketsMOJO.

According to the financial report, Trident Texofab’s performance for the quarter has been flat, with a score of 1 compared to -2 in the previous quarter. However, there are some positive aspects to the company’s financials. The Profit After Tax (PAT) for the quarter is the highest in the last five quarters at Rs 1.00 crore, indicating a positive trend in the near term. The Earnings per Share (EPS) for the quarter is also the highest in the last five quarters at Rs 0.99, showing an increase in profitability and higher earnings for shareholders.

On the other hand, there are some areas of concern for Trident Texofab. The Profit Before Tax less Other Income (PBT) for the quarter has fallen by -722.73% Year on Year (YoY) at Rs -1.81 crore, and the near term trend for PBT is negative. The Operating Profit (PBDIT) for the quarter is also the lowest in the last five quarters at Rs -0.28 crore, with a negative trend in the near term. The Operating Profit Margin for the quarter is also the lowest in the last five quarters at -1.06%, indicating a deterioration in the company’s efficiency. Additionally, the Non Operating Income for the quarter is 290.53% of the Profit Before Tax (PBT), which suggests that the company’s income from non-business activities is high and not sustainable in the long run.

Overall, Trident Texofab’s financial performance for the quarter ending September 2024 has been mixed, with some positive and negative aspects. Investors should carefully consider these factors before making any investment decisions.